US2009264371A1PendingUtilityA1

Antiproliferative peptides and antibodies for their detection

Assignee: BIOINCEPT LLCPriority: Jul 14, 2004Filed: Nov 26, 2008Published: Oct 22, 2009

Est. expiryJul 14, 2024(expired)· nominal 20-yr term from priority

Inventors:Eytan R. Barnea

C12Q 1/48G01N 2800/368A61K 38/00C07K 16/18C12N 2740/15022A61P 35/00C07K 14/005C07K 7/06C07K 2317/11G01N 33/575

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to developmental peptides and peptidomimetics thereof, which may be used therapeutically to inhibit abnormal cell proliferation of damaged cells, including cancer cells or virally infected cells. In one embodiment, a seven to eleven amino acid developmental peptide and methods of using the same is provided.

Claims

exact text as granted — not AI-modified

1 . A method of treating a proliferative disorder in a subject comprising administering to said subject a peptide selected from the group consisting of N-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH (SEQ ID NO: 1), N-Val-Leu-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH (SEQ ID NO: 2), N-Ile-Glu-Val-Leu-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH (SEQ ID NO: 3), N-Ile-Asp-Val-Leu-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH (SEQ ID NO: 4), N-Ile-Arg-Val-Leu-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH (SEQ ID NO: 5), N-Ile-Glu-Val-Thr-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH (SEQ ID NO: 6), N-Ile-Asp-Val-Thr-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH (SEQ ID NO: 7), and N-Ile-Arg-Val-Thr-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH (SEQ ID NO: 8). 
     
     
         2 . The method of  claim 1 , wherein said proliferative disorder is cancer. 
     
     
         3 . The method of  claim 1 , wherein said proliferative disorder is a viral infection. 
     
     
         4 . The method of  claim 1 , wherein an effective amount of said peptide is administered to said subject. 
     
     
         5 . The method of  claim 4 , wherein an effective amount of said peptide is 1 mg to 2000 mg. 
     
     
         6 . The method of  claim 4 , wherein an effective amount of said peptide is 1 mg to 1000 mg. 
     
     
         7 . The method of  claim 4 , wherein an effective amount of said peptide is 50 mg to 600 mg. 
     
     
         8 . The method of  claim 1  further comprising administering a therapeutic agent selected from the group consisting of chemotherapeutic agents, immune modulators, and angiogenic inhibitors. 
     
     
         9 . The method of  claim 1 , wherein said peptide is administered in a composition comprising a pharmaceutical carrier. 
     
     
         10 . The method of  claim 1 , wherein said peptide is SEQ ID NO: 1 (N-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH). 
     
     
         11 . The method of  claim 1 , wherein said peptide is SEQ ID NO: 2 (N-Val-Leu-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH). 
     
     
         12 . The method of  claim 1 , wherein said peptide is SEQ ID NO: 3 (N-Ile-Glu-Val-Leu-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH). 
     
     
         13 . The method of  claim 1 , wherein said peptide is SEQ ID NO: 4 (N-Ile-Asp-Val-Leu-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH). 
     
     
         14 . The method of  claim 1 , wherein said peptide is SEQ ID NO: 5 (N-Ile-Arg-Val-Leu-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH). 
     
     
         15 . The method of  claim 1 , wherein said peptide is SEQ ID NO: 6 (N-Ile-Glu-Val-Thr-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH). 
     
     
         16 . The method of  claim 1 , wherein said peptide is SEQ ID NO: 7 (N-Ile-Asp-Val-Thr-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH). 
     
     
         17 . The method of  claim 1 , wherein said peptide is SEQ ID NO: 8 (N-Ile-Arg-Val-Thr-Gly-Lys-Arg-Ile-Lys-Gly-Thr-OH).

Join the waitlist — get patent alerts

Track US2009264371A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.